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Background: The advent of global clinical trials has necessitated the use of English-based rating instruments in
diverse cultures where English is clearly not the primary language. The cross-cultural applicability of rating
instruments developed in one language with only one cultural group is an important issue in both research and
clinical settings where these instruments might be used. We examined the cross-cultural applicability of the
Montgomery-Asberg Depression Rating Scale (MADRS) in Japan.
Methods: As part of a rater-training program for a clinical trial in Japan, we assessed inter-rater agreement using
two videotaped MADRS interviews administered in Japanese and produced with English subtitles. We looked for
possible interpretational variance that might have been generated by cultural differences between Japanese raters
in Japan and English-speaking raters in the USA scoring the same interviews.
Results: The US and Japanese raters demonstrated high inter-rater agreement and no significant scoring difference
on the total MADRS score. The subtitles in English did not adversely affect the overall scoring.
We separately analyzed the 10 individual items from each of the two MADRS interviews used for rater training. Of
the 20 items, 18 were concordant between the US and Japanese raters. In one interview, the US raters scored
lassitude significantly higher (p = 0.013) and the inability to feel significantly lower (p = 0.037) than the Japanese
raters, reflecting a possible interpretational difference on these items.
Conclusion: Although developed in Europe, these findings support the general applicability of the MADRS to
assess the severity of depressive symptoms in Japan. We did note significant scoring differences on 2 of the 20
individual items, suggesting a possible cultural difference. It is possible that more interviews might have revealed
more interpretational differences. These findings highlight the need for cultural familiarity when assessing
psychiatric patients.
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Central nervous system clinical trials rely on reliable and
valid rating instruments to evaluate the efficacy of candi-
date drugs. These instruments have been translated and
validated in many languages in order to facilitate the
local (native) languages that are required in multi-
national trials. Generally, the training materials and
demonstration interviews used to establish inter-rater
reliability for rater certification are developed in English
with subtitles provided in the requisite local languages.
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reproduction in any medium, provided the orusing instruments developed in Western countries
(Europe or the USA), and conducted with English-
speaking subjects from Western countries, can be used
to effectively train and standardize scoring among raters
from non-Western nations. Clearly, there are cultural
differences in the assessment of psychiatric patients that
can influence ratings and adversely affect inter-rater
agreement [1-4]. Mackin et al. [4] showed significant
cultural differences in the assessment of acutely manic
subjects when the same videotaped interviews were shown
to English-speaking raters from India, the UK, and the
USA. They emphasized that effective training materials
need to be culturally ‘neutral’ in order to achieve inter-
rater agreement. However, there have been few studiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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views across cultures that did not speak English as a
primary language. Kalali et al. [3] noted cultural diffe-
rences on the subtitled Positive and Negative Syndrome
Scale (PANSS) interviews during rater training programs
conducted across six Eastern European countries speaking
six different languages. Alternatively, other studies [5-7]
have reported high concordance rates using subtitled
PANSS and the NSA-16 (Negative Symptom Assessment
scale) interviews with non-English-speaking raters from
multiple countries including Eastern Europe and Southeast
Asia. These reports used English-speaking interviews with
subtitles in the local languages. Recently, Friedmann et al.
[8] reversed the design and used Russian-language inter-
views of the Hamilton Rating Scale for Depression and
English subtitles. They demonstrated high concordance
rates between the Russian and American raters.
The Montgomery-Asberg Depression Rating Scale
(MADRS) is frequently used as a primary efficacy mea-
sure to assess patients with major depressive disorder
(MDD) in multi-national clinical trials [9]. In their initial
report, the authors’ asserted that the MADRS was
culturally neutral although the instrument was only field
tested in the UK and Sweden. The MADRS is used
throughout the world, but the universality and cultural
relevance of the 10 items have not been carefully assessed.
However, the clinical relevance of the MADRS (or any
other rating instrument) in clinical research or in practice
is contingent upon the validity of the selected items for
the culture being assessed. It is possible that some
MADRS items may generate different interpretations and
yield different scores in non-Western cultures.
The Japanese language and culture are distinctly dif-
ferent from countries in Western Europe or the USA.
Historically, the existence of depression as an illness was
suppressed in Japan, and suicide was often associated
with honor rather than a consequence of social problems
or depressive disease [10]. Clearly, these perceptions
about depression are very different from the beliefs and
attitudes commonly held in Western countries. In fact,
until recently, there was still some reluctance to acknow-
ledge major depressive disorder in Japan [10,11]. Long-
held traditional beliefs about responsibility, honor, and
productivity may influence the perception and scoring of
some MADRS items like reported sadness, lassitude,
inability to feel, pessimism, or even suicidal thoughts.
It was of some interest to examine the cross-cultural
applicability of the MADRS in a Japanese population of
depressed patients. Beyond the issue of inter-rater ag-
reement and data comparability, cultural validity is an
important issue whenever a rating instrument developed
in one language is used in another. To evaluate the
possibility that cultural differences may affect MADRS
scoring, we conducted a rater training program comparingtwo MADRS videotaped interviews conducted in Japan
and scored by Japanese and American raters. These
MADRS interviews were administered in Japanese and
were rated by US clinicians using the identical Japanese-
language MADRS interviews with corresponding English
subtitles.
We asked the following questions:
1. Can American clinicians using English subtitles
achieve equivalent scores to Japanese clinicians on
MADRS interviews conducted in Japanese?
2. Are there any individual items that reflect different
cultural interpretations of the MADRS instrument?
Methods
This study was conducted as part of a rater training and
certification program developed for a clinical trial being
conducted for patients with MDD in Japan. The rater
certification program consisted of three components:
didactic instruction about the MADRS, assessment of suc-
cessful scoring accuracy on two MADRS demonstration
video interviews, and assessment of research interviewing
competency based upon satisfactory administration of a
mock MADRS interview. The didactic training program
for the MADRS was developed in English (SDT, Clintara,
USA), translated into Japanese (AN, Keio University,
Japan), and presented in Japanese at an investigator
meeting held in Tokyo, Japan (February 2011) for these
clinical trials.
The MADRS is a well-known 10-item symptomatic
questionnaire developed over 30 years ago during the
era of tricyclic antidepressants to assess clinical change
during treatment [9]. The 10 MADRS items were chosen
from the 65-item Comprehensive Psychopathological
Rating Scale (CPRS) based upon their sensitivity to
changes with treatment on four antidepressant drugs
during a double-blind clinical trial of 54 English and 52
Swedish patients [9]. These 10 ‘best’ items included
sadness (both reported and observed), psychic inner
tension, reduced sleep, reduced appetite, concentration
difficulties, lassitude, inability to feel, pessimism, and
suicidal thoughts. Each of the 10 items has specific
descriptors and scoring anchors to facilitate scoring and
is scored from 1 to 6 with increasing evidence of seve-
rity. Total MADRS scores in the mid-20s generally
reflect moderate depression, and scores in the mid-30s
reflect moderate to severe depression [12,13].
In preparation for the rater-training program, five
MADRS interviews were videotaped for evaluation
purposes. The interviews were administered in Japanese
(AN) with Japanese volunteer subjects using a structured
interview guide (SIGMA) developed by Williams and
Kobak [14] and subsequently subtitled in English. No
informed consent was required because the subjects
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tients. The scripts were developed to reflect typical his-
tories and clinical presentations of depressed patients in
Japan. Each interview was transcribed into a Japanese
script, translated into English by the interviewer himself
(AN), and subsequently confirmed by an independent
translator in the USA prior to subtitling in English. An
effort was made to include in the subtitles the complete
text of the original interview as it had been spoken in
Japanese.
A panel of three Japanese raters from Keio University
(Tokyo, Japan) and three US raters from the Massachu-
setts General Hospital (Boston, MA, USA) was convened
before the investigator meeting to review each interview
for comprehension, relevance to a Japanese population,
and suitability for training and to establish an acceptable
individual item score range and ‘gold standard’ total
MADRS score. The consensus ‘gold’ score was used for
the assessment of the proportion of inter-rater agree-
ment (kappa statistic).
As planned, two MADRS interviews reflecting moder-
ate to severe depression were selected as most suitable
for the rater-training program and for the assessment of
inter-rater agreement.
Subject 1 was a 35-year-old married woman whose
preoccupation, sadness, and discouragement about her
fertility problems affected work performance and social
interactions due to her distractibility, sluggishness,
shame, and loss of interest in friends and hobbies. The
clinical presentation met DSM-IV criteria for major de-
pressive disorder although it was clear that psychosocial
stress was a confounding factor contributing to her
mood disorder.
Subject 5 was a 40-year-old man who complained of
constant sadness, fatigue, concentration difficulties, and
excessive stress related to his inability to be more pro-
ductive and advance in his job. This presentation of ‘fa-
tigue depression’ is common in Japan and had clearly
affected this subject’s interpersonal relations and well as
his work performance.
The selected MADRS interviews (subjects 1 and 5)
were shown to the Japanese raters at the investigator
meeting. The Japanese clinician raters recognized these
volunteer subjects as believable cases of depression con-
sistent with the type of patients they had seen in their
practice. Subsequently, a small group of experienced US
raters (n = 23) observed and scored the same two
videotaped interviews containing the corresponding
English subtitles. The US raters did not speak or under-
stand Japanese. Demographic data were collected from
all raters including education, clinical experience, and
rating experience with the MADRS instrument. Statis-
tical analysis included Student’s t test comparison (with
Bonferroni correction for multiple comparisons) and akappa statistic to determine the proportion of inter-rater
agreement based upon the gold standard consensus
panel score [15,16].Results
Demographics
Thirty-four Japanese raters and 23 US raters participated
in this reliability study. The Japanese raters were all male
physicians (mean age = 51.97 ± 8.08 years) with 22.7 ±
7.87 years of clinical experience (range 9 to 38 years)
and 5.25 ± 7.87 years of MADRS rating experience
(range 1 to 15 years). Eight of the Japanese raters had
two or fewer years of MADRS rating experience. The US
raters included male (n = 11) and female (n = 12) physi-
cians, psychologists, and nurses (mean age = 45.54 ±
9.54 years) with 14.6 ± 5.81 years of clinical experience
(range 5 to 42 years) and 6.15 ± 8.12 years of MADRS
rating experience (range 4 to 15 years). None of the US
raters spoke Japanese.Inter-rater agreement
Both the Japanese and US raters demonstrated high inter-
rater agreement on the two MADRS interviews that were
scored. The mean total MADRS score for the first inter-
view (subject 1) was 33.31 ± 3.91 (SD) for the Japanese
raters and 33.57 ± 3.04 for the US raters (t = 0.260;
degrees of freedom (df) = 53; p = not significant (ns)).
Similarly, the mean total MADRS score for the second
interview (subject 5) was 29.76 ± 2.83 for the Japanese
raters and 30.77 ± 2.64 for the US raters (t = 1.34; df = 54;
p = ns). Analysis of the variance between the Japanese and
US sets of MADRS ratings was also not significant for
subject 1 (F = 1.68; p = ns) or subject 5 (F = 1.17; p = ns).
Only four of the Japanese raters (12.9%) required rating
remediation prior to meeting qualification requirements
to rate in the clinical study. Among the US raters, there
were no significant scoring differences related to educa-
tion or between men and women raters.
Figures 1 and 2 reveal similar distributions of the total
MADRS scores between the US and Japanese raters on
both interviews. Of 54 raters, 45 (83%) were within one
standard deviation of the median MADRS score for sub-
ject 1, and of 56 raters, 42 (76%) for subject 5. The US
raters watching the Japanese-language MADRS inter-
views with English subtitles demonstrated high scoring
concordance with the Japanese raters who watched the
same interviews in their own language. The Kappa stat-
istic measuring the proportion of agreement among all
raters (as a categorical measure) was 0.92 for subject 1
and 0.86 for subject 5 using the accepted ‘standard’
scores previously derived by the consensus panel of
three Japanese and three US raters.
Figure 1 Total MADRS score distribution for subject 1.
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As shown in Tables 1 and 2, there were no significant
scoring differences between the US and Japanese raters
on the majority of individual MADRS items (using
Bonferroni correction for multiple comparisons). How-
ever, the US raters scored lassitude (item 7) significantly
higher (p = 0.013) and the inability to feel (item 8)
significantly lower (p = 0.037) than Japanese raters on
subject 1. There was also a non-significant trend on item
7 in subject 5 (p = 0.160).
Discussion
Contemporary clinical trials that pursue new drug deve-
lopment are often multi-national, involving multiple
languages and diverse cultural groups. Researchers
cannot presume that rating instruments developed and
tested in Western countries can reliably assess illness
severity and accurately measure serial change in patients
from non-Western cultures. The issue of cross-cultural
applicability is important in any clinical situation where
rating instruments developed in one language are used
in another. We examined the cross-cultural scoring
agreement on one instrument (the MADRS) that was
developed in two European countries as part of a clinicalFigure 2 Total MADRS score distribution for subject 5.trial for patients with major depressive disorder. We con-
ducted a comprehensive rater-training program that
included two MADRS interviews administered in Japanese
with Japanese subjects for certification of the Japanese
raters. These same MADRS interviews were shown to the
US raters with accompanying English subtitles to ascertain
inter-rater scoring agreement and to explore possible
cultural differences in interpretation and scoring.
The US and Japanese raters demonstrated high inter-
rater agreement and no significant mean total MADRS
scoring differences. Most raters scored within one stand-
ard deviation of the median MADRS score on both in-
terviews. Clearly, the English subtitles did not adversely
affect the high concordance observed between the US
and Japanese scoring.
We analyzed the 20 individual items contained in the
two MADRS interviews to explore possible interpre-
tational differences between the US and Japanese raters.
Although there were no significant scoring differences
on 18 items (using a Bonferroni correction for multiple
comparisons), two significant scoring differences bet-
ween the rater groups were noted in subject 1. The US
raters scored lassitude significantly higher (p = 0.013)
and the inability to feel significantly lower (p = 0.037)
than Japanese raters. Subject 5 revealed no significant
item scoring differences. Subject 5 depicted a man pre-
senting with overwork (fatigue) depression, a condition
that is commonly seen in Japan but is not diagnosed or
recognized by most American clinicians [10,11,17]. We
found no significant scoring differences on depressed
mood, anxiety, lassitude, or pessimism in this subject as
scored by the US or Japanese raters. However, there was
a non-significant trend (p = 0.160 with the Bonferroni
correction) with US raters scoring higher than Japanese
raters on the scoring of item 7 (lassitude) in subject 5.
It is reasonable to presume that Japanese raters are
more attuned than US raters to the clinical relevance
and nuance of a Japanese patient presenting with
expressed lack of initiation (sluggishness), and unexpressed
numbness (inability to feel). These scoring differences
may reflect genuine cultural differences in the interpre-
tation of the MADRS items. Alternatively, these scoring
differences may reflect more about the cultural familiarity
of the Japanese clinician with the clinical presentation of
Japanese patients than to specific cultural beliefs about
depressive mood, anxiety, lassitude, or the inability to feel.
The structured research interview format of the
MADRS assesses the severity of depressive symptoms over
the past 7 days and specifically dissociates diagnoses from
the assessment [9,14]. The descriptors and scoring an-
chors relate to the specific symptoms and are meant to be
generic guides. Further, the standardized methods used
for investigator training seek to minimize any interpre-
tational scoring differences by improving the precision of
Table 1 MADRS individual item analysis for subject 1
MADRS itema 1 2 3 4 5 6 7 8 9 10
Japanese raters
Mean 3.28 3.72 4.25 2.56 3.16 3.84 3.53 1.69
STD 0.88 0.63 0.99 0.58 0.51 0.91 0.57 0.51 0.80 0.59
US raters
Mean 3.83 4.00 3.39 3.39 4.04 2.43 3.83 3.39 3.43 1.83
STD 0.58 0.67 0.78 0.58 0.21 0.73 0.89 0.58 0.66 0.49
T value −1.26 −1.58 −0.44 2.06 1.84 0.56 −3.40 3.04 0.47 −0.92
Pb ns ns ns ns ns ns 0.013 0.037 ns ns
aMADRS items: 1 (apparent sadness), 2 (reported sadness), 3 (inner tension), 4 (reduced sleep), 5 (reduced appetite), 6 (concentration difficulties), 7 (lassitude), 8
(inability to feel), 9 (pessimistic thoughts), 10 (suicidal thoughts). bBonferroni correction for multiple comparisons. STD standard, ns not significant.
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might be less likely to influence the MADRS scores. How-
ever, the findings in this small study suggest that there
might be interpretational differences between US and
Japanese raters on some MADRS items. The interpre-
tation of lassitude or the inability to feel may be influenced
by cultural views and may not be as neutral as the assess-
ment of appetite or sleep. Of course, our findings must be
interpreted with caution given its small size. We used only
two MADRS interviews in this study that were conducted
with two volunteer subjects (not patients with MDD) pre-
senting with relatively similar depressive symptom severity
(MADRS approximately 30 to 34). Clearly, our findings
are limited by virtue of the small number of individual
MADRS items assessed. It is conceivable that a larger
sample of interviews might have revealed more cultural
interpretational differences that were not uncovered in
this small analysis. Further, our study was conducted in
only one Asian country and may not be applicable to
other Asian cultures.
However, given these limitations, our findings in this
cross-cultural MADRS analysis between Japanese and US
raters do provide some support for the usefulness of the
MADRS to assess the overall severity of depressive symp-
toms in distinctly different cultural groups. The findings
also highlight the importance of using a clinician raterTable 2 MADRS individual item analysis for subject 5
MADRS itema 1 2 3 4
Japanese raters
Mean 3.82 3.97 3.41 2.41
STD 0.52 0.46 0.70 0.61
US raters
Mean 3.73 4.05 3.59 2.68
STD 0.46 0.58 0.50 0.48
T value 0.71 −0.54 −1.04 −1.76
Pb ns ns ns ns
aMADRS items: 1 (apparent sadness), 2 (reported sadness), 3 (inner tension), 4 (redu
(inability to feel), 9 (pessimistic thoughts), 10 (suicidal thoughts). bBonferroni correcwho is familiar with the culture of the patient being
assessed.Conclusion and future directions
Researchers and clinicians cannot automatically presume
that rating instruments developed and tested in Western
countries can accurately assess illness severity and meas-
ure serial change in patients from non-Western cultures.
In this study, we found that the MADRS, an instrument
originally developed and validated in the UK and Sweden,
was reliable when scored by the Japanese raters in
Japanese-language videotaped interviews and by the US
raters observing subtitled English translations of these
same interviews. Given the multi-national nature of global
studies, it is reassuring to provide this degree of confir-
mation among diverse cultural groups. However, cultural
familiarity between rater and patient is still important to
achieve the most clinically relevant information for precise
scoring. In fact, two MADRS items that may be suscep-
tible to cultural interpretations (lassitude and the inability
to feel) were scored significantly differently by the US and
Japanese raters in one of these interviews. Our findings
are based on only two interviews and suggest that more
extensive research is warranted with real patients who are
seen in real clinical settings.5 6 7 8 9 10
0.12 3.91 3.29 4.09 3.24 1.50
0.41 0.51 0.87 0.93 0.89 0.62
0.00 4.14 3.82 4.32 3.32 1.14
0.00 0.64 0.59 0.48 0.72 0.47
1.34 −1.45 −2.48 −1.07 −0.37 2.36
ns ns 0.160 ns ns ns
ced sleep), 5 (reduced appetite), 6 (concentration difficulties), 7 (lassitude), 8
tion for multiple comparisons. STD standard, ns not significant.
Targum et al. Annals of General Psychiatry 2013, 12:9 Page 6 of 6
http://www.annals-general-psychiatry.com/content/12/1/9Abbreviations
MADRS: Montgomery-Asberg Depression Rating Scale; MDD: Major
depressive disorder; PANSS: Positive and negative syndrome scale.
Competing interests
SDT, MD has received honoraria or grants from the following: Acadia,
Acumen, Alkermes Inc., Amgen, AstraZeneca, BioMarin, BrainCells Inc.,
CeNeRx, Cephalon, Clintara LLC, CTNI MGH, EnVivo Pharmaceuticals,
Euthymics, Eli Lilly and Company, EnVivo Pharmaceuticals, Forest Research,
Functional Neuromodulation Inc., GlaxoSmithKline, Johnson & Johnson PRD,
INC Research, Methylation Sciences Inc., NeoSync, Neurophage, Novartis
Pharmaceuticals, Nupathe, Parexel International, PRA International, Prana
Biotechnology Ltd., ReViva, Roche Labs, Sophiris, Sunovion, Targacept,
Theravance, Transcept, and Wyeth labs.
AN, MD, PhD received grants from Eli Lilly, Pfizer Inc., and Igaku-Shoin.
YS, MD, PhD received grants from Astra Zeneca, Pfizer, Sanofi-Aventis,
GlaxoSmithKline, Eli Lilly, Abbott, Novartis, MSD, Asahi-kasei, Takeda, Daiichi-Sankyo,
Japan Chemical Research, EPS, Taisho, Ajinomoto, Tasly, Parexel, and Icon.
Authors’ contributions
All listed authors in this manuscript have contributed substantially to the
design, execution, analysis, and writing of the manuscript. All authors read
and approved the final manuscript.
Authors’ information
SDT is the scientific director and founder of Clintara LLC (Boston MA) and on
the consulting faculty at Massachusetts General Hopsital (Boston, MA, USA).
AN is the director of the Translational Medical Center, National Center of
Neurology and Psychiatry and on the faculty of the Department of
Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. YS is the
director of the Center for Clinical Research, Keio University School of
Medicine, Tokyo, Japan.
Acknowledgments
The authors thank Tina Oakes (Eli Lilly and Company) and Maurizio Fava
(Massachusetts General Hospital). In addition, the staff from Keio University
(Tokyo, Japan), Clintara LLC and CTNI-Massachusetts General Hospital who
participated in the coordination of this program are also acknowledged.
Financial support for this study came from a research grant from Clintara LLC.
Author details
1Clintara LLC, 505 Tremont Street, #907, Boston, MA 02116, USA.
2Massachusetts General Hospital, Boston, MA 02114, USA. 3Translational
Medical Center, National Center of Neurology and Psychiatry and the
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo
160-8582, Japan. 4Center for Clinical Research, Keio University School of
Medicine, Tokyo 160-8582, Japan.
Received: 21 September 2012 Accepted: 22 March 2013
Published: 3 April 2013
References
1. Savage C, Leighton A, Leighton D, Murph J, Murphy J, Leighton A: The
problem of cross-cultural identification of psychiatric disorders. In
Approaches to Cross-Cultural Psychiatry. New York: Cornell University Press;
1965:4.
2. Egeland JA, Hostetter AM, Eshleman SK: Amish Study, III: the impact of
cultural factors on diagnosis of bipolar illness. Am J Psychiatry 1983,
140:67–71.
3. Kalali AH, West MD, Targum SD: Multinational qualification of raters on
the PANSS rating scale. In International Congress on Schizophrenia Research:
March 2003. Colorado Springs; 2003.
4. Mackin P, Targum SD, Kalali A, Rom D, Young AH: Culture and assessment
of manic symptoms. British Journal of Psychiatry 2006, 12:379–380.
5. Targum SD, Mullen J, Paulsson B, Vasovicova P: “Multinational inter-rater
consistency across six separate investigator meetings”. In 17th Annual
ECNP Congress: October 10 2004. Stockholm; 2004.
6. Friedmann B, Riordan H, Braxton E, Weber CJ, Murphy MF, Cutler NR: The
effect of simultaneous translations and experience on positive and
negative syndrome scale (PANSS) scoring performance for EasternEuropean raters. In 49th Annual NCDEU Meeting; July 1 2009. Hollywood, FL;
2009.
7. Daniel DG, Alphs L, Cazorla P, Bartko JJ, Panagides J: Training for
assessment of negative symptoms of schizophrenia across languages
and cultures: comparison of the NSA-16 with the PANSS negative
subscale and negative symptom factor. Clin Schizophr Relat Psychoses
2011, 5(2):87–94.
8. Friedmann B, Braxton E, Riordan H, Weber CJ, Murphy MF, Cutler NR: A
comparison of rating quality between subtitled and spoken Hamilton
depression rating scale interviews. Eur Neuropsychopharmacol 2009, 19:3–4.
9. Montgomery SA, Asberg M: A new depression scale designed to be
sensitive to change. Br J Psychiatry 1979, 134:382–389.
10. Kitanaka J: Depression in Japan: Psychiatric Cures for a Society in Distress.
Princeton: Princeton University Press; 2001.
11. Kitanaka J: Diagnosing suicides of resolve: psychiatric practice in
contemporary Japan. Cult Med Psychiatry 2008, 3(2):152–176.
12. Benazzi F: Severity gradation of the Montgomery Asberg Depression Rating
Scale (MADRAS) in outpatients. J Psychiatry Neurosci 1999, 24(1):51–52.
13. Snaith RP, Harrop FM, Newby DA, Teale C: Grade scores of the
Montgomery-Asberg depression and the clinical anxiety scales.
Br J Psychiatry 1986, 148:599–601.
14. Williams JBW, Kobak KA: Development and reliability of a structured
interview guide for the Montgomery-Asberg Depression Rating Scale
(SIGMA). Br J Psychiatry 2008, 192:52–58.
15. Bland JM, Altman DG: Multiple significance tests: the Bonferroni method.
British Medical Journal 1995, 10(6973):170.
16. Fleiss JL: The measurement of interrater agreement. In Statistical Methods
for Rates and Proportions. Edited by Fleiss JL. New York: John Wiley & Sons
Inc; 1981:212–236.
17. Iwasaki K, Takahashi M, Nakata A: Health problems due to long working
hours in Japan: Working hours, workers’ compensation (Karoshi), and
preventive measures. Ind Health 2006, 44:537–540.
doi:10.1186/1744-859X-12-9
Cite this article as: Targum et al.: A cross-cultural comparison study of
depression assessments conducted in Japan. Annals of General Psychiatry
2013 12:9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
